A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Inclusion Criteria: * Male or female patients 6 years or older * Laboratory confirmed diagnosis of EBS-sev due to KRT5 or 14 mutation (autosomal) * Mean daily number of new blisters \>3. * Subject/caregiver agrees not to use any topical therapies other than the investigator approved Exclusion Criteria: * \- EBS lesions requiring oral therapy to treat an infection * Use of any diacerein containing product within 6 months prior to Visit 1 * Use of systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Visit 1 * Use of systemic steroidal therapy within 30 days prior to Visit 1 * Use of any systemic product that, in the opinion of the investigator, might put the subject at undue risk by study participation or interferes with the study assessments within 30 days prior to Visit 1